A lack of consensus exists regarding acute flare management in hidradenitis suppurativa (HS). Intramuscular triamcinolone (IMTAC) therapy is useful in numerous inflammatory conditions; however, it has not been investigated for acute HS flares.
Objective
To evaluate the efficacy and patient experience associated with IMTAC therapy for acute, severe HS flares.
Methods
Retrospective analysis and surveys of 45 HS patients were conducted at Albert Einstein College of Medicine/ Montefiore HS Center, Bronx, NY, USA.
Results
Follow-up visits 6.77 (4.45) weeks after IMTAC therapy revealed significant reductions in mean HS-Physician Global Assessment (PGA) (P < .001), C-Reactive Protein (CRP) (P = .03), increased hemoglobin (P = .004), and improved pain scores (P < .001). Adjusting for age, sex and concomitant medications, multivariate analysis yielded significantly reduced pain (P = .02) and increased hemoglobin (P = .03). Patient surveys indicate that IMTAC was well-tolerated, as reflected in positive mean responses for satisfaction (29 [64%]) and willingness to receive IMTAC injections again (42 [93%]).
Conclusions
These novel findings demonstrate that IMTAC is a safe, effective, and well accepted adjunct for acute HS management.
JemecGBE. Clinical practice. Hidradenitis suppurativa. N Engl J Med. 2012;366(2):158-164.doi:10.1056/NEJMcp101416322236226
2.
GoldburgSR.StroberBE.PayetteMJ. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol. 2020;82(5):1045-1058.doi:10.1016/j.jaad.2019.08.09031604104
3.
BanerjeeA.McNishS.ShanmugamVK. Interferon-gamma (IFN-γ) is elevated in wound exudate from hidradenitis suppurativa. Immunol Invest. 2017;46(2):149-158.doi:10.1080/08820139.2016.123086727819528
4.
van der ZeeHH.de RuiterL.van den BroeckeDG.DikWA.LamanJD.PrensEP. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol. 2011;164(6):1292-1298.doi:10.1111/j.1365-2133.2011.10254.x21332464
5.
MoranB.SweeneyCM.HughesRet al. Hidradenitis suppurativa is characterized by dysregulation of the Th17: treg cell axis, which is corrected by anti-TNF therapy. J Invest Dermatol. 2017;137(11):2389-2395.doi:10.1016/j.jid.2017.05.03328652108
6.
FloodKS.PorterML.KimballAB. Biologic treatment for hidradenitis suppurativa. Am J Clin Dermatol. 2019;20(5):625-638.doi:10.1007/s40257-019-00439-531140067
7.
GhiasMH.JohnstonAD.KutnerAJ.MichelettiRG.HosgoodHD.CohenSR. High-dose, high-frequency infliximab: a novel treatment paradigm for hidradenitis suppurativa. J Am Acad Dermatol. 2020;82(5):1094-1101.doi:10.1016/j.jaad.2019.09.07131589948
8.
BettoliV.Join-LambertO.NassifA. Antibiotic treatment of hidradenitis suppurativa. Dermatol Clin. 2016;34(1):81-89.doi:10.1016/j.det.2015.08.01326617361
9.
GolbariNM.PorterML.KimballAB. Antiandrogen therapy with spironolactone for the treatment of hidradenitis suppurativa. J Am Acad Dermatol. 2019;80(1):114-119.doi:10.1016/j.jaad.2018.06.06330003993
10.
RitzJP.RunkelN.HaierJ.BuhrHJ. Extent of surgery and recurrence rate of hidradenitis suppurativa. Int J Colorectal Dis. 1998;13(4):164-168.doi:10.1007/s0038400501599810520
11.
HessamS.SandM.GambichlerT.BecharaFG. Correlation of inflammatory serum markers with disease severity in patients with hidradenitis suppurativa (HS). J Am Acad Dermatol. 2015;73(6):998-1005.doi:10.1016/j.jaad.2015.08.05226410359
12.
AltmanSR.CriswellSL. Dynamic leukocyte populations are associated with early- and late-stage lesions in hidradenitis suppurativa. J Histochem Cytochem. 2021;69(3):191-201.doi:10.1369/002215542097853533238789
13.
Jiménez-GalloD.de la Varga-MartínezR.Ossorio-GarcíaL.Albarrán-PlanellesC.RodríguezC.Linares-BarriosM. The clinical significance of increased serum proinflammatory cytokines, C-reactive protein, and erythrocyte sedimentation rate in patients with hidradenitis suppurativa. Mediators Inflamm. 2017;2017:1-8.doi:10.1155/2017/245040128769536
14.
AndrianoTM.BeneshG.BabbushKM.HosgoodHD.LinJ.CohenSR. Serum inflammatory markers and leukocyte profiles accurately describe hidradenitis suppurativa disease severity. Int J Dermatol. 2022;61(10):1270-1275.doi:10.1111/ijd.1624435543428
15.
GarelikJ.BabbushK.GhiasM.CohenSR. Efficacy of high-dose intralesional triamcinolone for hidradenitis suppurativa. Int J Dermatol. 2021;60(2):217-221.doi:10.1111/ijd.1512432808305
16.
RiisPT.BoerJ.PrensEPet al. Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): a case series. J Am Acad Dermatol. 2016;75(6):1151-1155.doi:10.1016/j.jaad.2016.06.04927692735
17.
WongD.WalshS.AlhusayenR. Low-dose systemic corticosteroid treatment for recalcitrant hidradenitis suppurativa. J Am Acad Dermatol. 2016;75(5):1059-1062.doi:10.1016/j.jaad.2016.06.00127745633
18.
AlikhanA.SayedC.AlaviAet al. North American clinical management guidelines for hidradenitis suppurativa: a publication from the United States and Canadian hidradenitis suppurativa foundations: part II: topical, intralesional, and systemic medical management. J Am Acad Dermatol. 2019;81(1):91-101.doi:10.1016/j.jaad.2019.02.06830872149
19.
ZouboulisCC.DesaiN.EmtestamLet al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol. 2015;29(4):619-644.doi:10.1111/jdv.1296625640693
20.
ThomasLW.ElsensohnA.BergheimT.ShiuJ.GanesanA.SecrestA. Intramuscular steroids in the treatment of dermatologic disease: a systematic review. J Drugs Dermatol. 2018;17(3):323-329.29537450
21.
YuSH.DruckerAM.LebwohlM.SilverbergJI. A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. J Am Acad Dermatol. 2018;78(4):733doi:10.1016/j.jaad.2017.09.07429032119
22.
PatelZS.HoffmanLK.BuseDCet al. Pain, psychological comorbidities, disability, and impaired quality of life in hidradenitis suppurativa [corrected]. Curr Pain Headache Rep. 2017;21(12):49doi:10.1007/s11916-017-0647-329094219
23.
NielsenRM.Lindsø AndersenP.SigsgaardV.RiisPT.JemecGB. Pain perception and depression in patients with hidradenitis suppurativa. Br J Dermatol. 2020;182(1):e25-e74.doi:10.1111/bjd.1865630919930
24.
van StraalenKR. Chronic pain in hidradenitis suppurativa explained through the process of central sensitization. JAMA Dermatol. 2020;156(6):615-616.doi:10.1001/jamadermatol.2020.022532267476
25.
ShoenfeldY.GurewichY.GallantLA.PinkhasJ. Method and duration of administration on the degree of leukocytosis. Am J Med. 1981;71(5):773-778.
26.
AlshehriS.EljaalyK.AlshibaniM.KatzM. Impact of single-dose systemic glucocorticoids on blood leukocytes in hospitalized adults. Journal of Applied Hematology. 2020;11(3):116-121.
27.
den UylD.van RaalteDH.NurmohamedMTet al. Metabolic effects of high-dose prednisolone treatment in early rheumatoid arthritis: balance between diabetogenic effects and inflammation reduction. Arthritis Rheum. 2012;64(3):639-646.doi:10.1002/art.3337821953589
28.
HuangCM.LowesMA.CsertiC.AlaviA. Hemoglobin levels and serum C-reactive protein in patients with moderate to severe hidradenitis suppurativa. J Cutan Med Surg. 2019;23(5):501-506.doi:10.1177/120347541985896331253065
29.
SolimanYS.ChaitowitzM.HoffmanLK.LinJ.LowesMA.CohenSR. Identifying anaemia in a cohort of patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2020;34(1):e5-e8.doi:10.1111/jdv.1583731374127
30.
GhiasMH.JohnstonAD.BabbushKM.KutnerAJ.HosgoodHD.LowesMA. Hepcidin levels can distinguish anemia of chronic disease from iron deficiency anemia in a cross-sectional study of patients with hidradenitis suppurativa. J Am Acad Dermatol. 2021doi:10.1016/j.jaad.2021.03.090
31.
KirbyJS.MillerJJ.AdamsDR.LeslieD. Health care utilization patterns and costs for patients with hidradenitis suppurativa. JAMA Dermatol. 2014;150(9):937-944.doi:10.1001/jamadermatol.2014.69124908260
32.
KourisA.PlatsidakiE.ChristodoulouCet al. Quality of life and psychosocial implications in patients with hidradenitis suppurativa. Dermatology. 2016;232(6):687-691.doi:10.1159/00045335528052274
33.
AlaviA.AnooshirvaniN.KimWB.CouttsP.SibbaldRG. Quality-of-life impairment in patients with hidradenitis suppurativa: a Canadian study. Am J Clin Dermatol. 2015;16(1):61-65.doi:10.1007/s40257-014-0105-525432664
34.
GooderhamM.PappK. The psychosocial impact of hidradenitis suppurativa. J Am Acad Dermatol. 2015;73(5 Suppl 1):S19-S22.doi:10.1016/j.jaad.2015.07.05426470609
35.
ReddyS.AnanthakrishnanS.GargA. A prospective observational study evaluating hypothalamic-pituitary-adrenal axis alteration and efficacy of intramuscular triamcinolone acetonide for steroid-responsive dermatologic disease. J Am Acad Dermatol. 2013;69(2):226-231.doi:10.1016/j.jaad.2013.02.00523545370
MikhailGR.SweetLC.MellingerRC. Parenteral long-acting corticosteroids: effect on hypothalamic-pituitary-adrenal function. Ann Allergy. 1973;31(7):337-343.4352151
38.
GargA.BirabaharanM.StrunkA. Prevalence of type 2 diabetes mellitus among patients with hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2018;79(1):71-76.doi:10.1016/j.jaad.2018.01.01429339240
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
